Skip to main content
Erschienen in: Annals of Hematology 11/2012

01.11.2012 | Original Article

Radiotherapy for solitary plasmacytoma of bone and soft tissue

Outcomes and prognostic factors

verfasst von: Yang-Gun Suh, Chang-Ok Suh, Jin Seok Kim, Soo-Jeong Kim, Hae Ok Pyun, Jaeho Cho

Erschienen in: Annals of Hematology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

We investigated treatment outcomes of radiotherapy for solitary plasmacytoma (SP) and prognostic factors affecting survival. Between 1996 and 2010, a total of 38 patients were treated with radiotherapy for histologically proven plasmacytoma without evidence of multiple myeloma. Among these, 16 and 22 patients had SP originating from extramedullary soft tissue (EMP) and bone, respectively. Thirteen patients received adjuvant chemotherapy, and three patients underwent surgery prior to radiotherapy. At a median follow-up of 50 months (range, 8–142), radiotherapy demonstrated excellent local control (5- and 10-year local control rates, 81 %). However, the 10-year multiple myeloma-free survival (MMFS) was 54 % and the 10-year overall survival (OS) rates was 35 %. Solitary bone plasmacytoma (SBP) more frequently progressed to multiple myeloma (MM) than EMP (10-year MMFS, 0 % vs. 71 %, p = 0.02). Radiotherapy with doses ≥40 Gy demonstrated better local control (10-year LC, 100 % vs. 60 %, p = 0.04) in SBP. In the multivariate analysis, elevated β2-microglobulin was a significantly unfavorable prognostic factor affecting OS (p = 0.03). In conclusion, radiotherapy effectively treated SP without significant toxicity. However, progression to MM presents a challenging problem. Novel therapeutics are needed for patients with unfavorable prognostic factors.
Literatur
1.
Zurück zum Zitat Knowling MA, Harwood AR, Bergsagel DE (1983) Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1:255–262PubMed Knowling MA, Harwood AR, Bergsagel DE (1983) Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1:255–262PubMed
2.
Zurück zum Zitat Dimopoulos MA, Hamilos G (2002) Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 3:255–259PubMedCrossRef Dimopoulos MA, Hamilos G (2002) Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 3:255–259PubMedCrossRef
3.
Zurück zum Zitat Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85:2305–2314PubMedCrossRef Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85:2305–2314PubMedCrossRef
4.
Zurück zum Zitat Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ (1997) Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer 75:921–927PubMedCrossRef Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, Farrington WT, Slevin NJ (1997) Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer 75:921–927PubMedCrossRef
5.
Zurück zum Zitat Bolek TW, Marcus RB, Mendenhall NP (1996) Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 36:329–333PubMedCrossRef Bolek TW, Marcus RB, Mendenhall NP (1996) Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 36:329–333PubMedCrossRef
6.
Zurück zum Zitat Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, Landmann C, Castelain B, Buijsen J, Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, Nguyen TD, Studer G, Cooper R, Sengoz M, Scandolaro L, Zouhair A (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64:210–217PubMedCrossRef Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, Landmann C, Castelain B, Buijsen J, Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, Nguyen TD, Studer G, Cooper R, Sengoz M, Scandolaro L, Zouhair A (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64:210–217PubMedCrossRef
7.
Zurück zum Zitat Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (1998) Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41:1063–1067PubMedCrossRef Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (1998) Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 41:1063–1067PubMedCrossRef
8.
Zurück zum Zitat Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol) 16:405–413CrossRef Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol) 16:405–413CrossRef
9.
Zurück zum Zitat Kumar S (2008) Solitary plasmacytoma: is radiation therapy sufficient? Am J Hematol 83:695–696PubMedCrossRef Kumar S (2008) Solitary plasmacytoma: is radiation therapy sufficient? Am J Hematol 83:695–696PubMedCrossRef
10.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
11.
Zurück zum Zitat Mayr NA, Wen BC, Hussey DH, Burns CP, Staples JJ, Doornbos JF, Vigliotti AP (1990) The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 17:293–303PubMedCrossRef Mayr NA, Wen BC, Hussey DH, Burns CP, Staples JJ, Doornbos JF, Vigliotti AP (1990) The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 17:293–303PubMedCrossRef
12.
Zurück zum Zitat Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69:1513–1517PubMedCrossRef Holland J, Trenkner DA, Wasserman TH, Fineberg B (1992) Plasmacytoma. Treatment results and conversion to myeloma. Cancer 69:1513–1517PubMedCrossRef
13.
Zurück zum Zitat Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Stewart AK (2001) Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50:113–120PubMedCrossRef Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Stewart AK (2001) Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50:113–120PubMedCrossRef
14.
Zurück zum Zitat Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Oner FD, Landmann C, Castelain B, Ozsahin M (2006) Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6:118PubMedCrossRef Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Oner FD, Landmann C, Castelain B, Ozsahin M (2006) Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6:118PubMedCrossRef
15.
Zurück zum Zitat Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alexanian R (1992) Curability of solitary bone plasmacytoma. J Clin Oncol 10:587–590PubMed Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alexanian R (1992) Curability of solitary bone plasmacytoma. J Clin Oncol 10:587–590PubMed
16.
Zurück zum Zitat Chak LY, Cox RS, Bostwick DG, Hoppe RT (1987) Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol 5:1811–1815PubMed Chak LY, Cox RS, Bostwick DG, Hoppe RT (1987) Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol 5:1811–1815PubMed
17.
Zurück zum Zitat Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA (1989) Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 16:43–48PubMedCrossRef Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA (1989) Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 16:43–48PubMedCrossRef
18.
Zurück zum Zitat Jawad MU, Scully SP (2009) Skeletal plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol 2:41PubMedCrossRef Jawad MU, Scully SP (2009) Skeletal plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol 2:41PubMedCrossRef
19.
Zurück zum Zitat Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (2002) Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94:1532–1537PubMedCrossRef Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R (2002) Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 94:1532–1537PubMedCrossRef
20.
Zurück zum Zitat Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ 3rd, Dispenzieri A, Katzmann JA (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108:1979–1983PubMedCrossRef Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ 3rd, Dispenzieri A, Katzmann JA (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108:1979–1983PubMedCrossRef
21.
Zurück zum Zitat Duc J, Morel B, Peitrequin R, Frei PC (1988) Identification of monoclonal gammopathies: a comparison of immunofixation, immunoelectrophoresis and measurements of kappa- and lambda-immunoglobulin levels. J Clin Lab Immunol 26:141–146PubMed Duc J, Morel B, Peitrequin R, Frei PC (1988) Identification of monoclonal gammopathies: a comparison of immunofixation, immunoelectrophoresis and measurements of kappa- and lambda-immunoglobulin levels. J Clin Lab Immunol 26:141–146PubMed
22.
Zurück zum Zitat Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, Vazquez L, Garcia-Larana J, Sureda A, Rubia JD, Conde E, Martinez R, Perez-Equiza K, Moraleda JM, Leon A, Besalduch J, Cabrera R, Miguel JD, Morales A, Garcia-Ruiz JC, Diaz-Mediavilla J, San-Miguel J (2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109:438–446PubMedCrossRef Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, Vazquez L, Garcia-Larana J, Sureda A, Rubia JD, Conde E, Martinez R, Perez-Equiza K, Moraleda JM, Leon A, Besalduch J, Cabrera R, Miguel JD, Morales A, Garcia-Ruiz JC, Diaz-Mediavilla J, San-Miguel J (2000) Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109:438–446PubMedCrossRef
23.
Zurück zum Zitat Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420PubMedCrossRef Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420PubMedCrossRef
24.
Zurück zum Zitat Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN (1995) Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 71:128–133PubMedCrossRef Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN (1995) Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 71:128–133PubMedCrossRef
25.
Zurück zum Zitat Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC (1996) Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14:111–117PubMedCrossRef Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-Maqueo JC (1996) Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 14:111–117PubMedCrossRef
26.
Zurück zum Zitat Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233PubMedCrossRef Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233PubMedCrossRef
27.
Zurück zum Zitat Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085PubMedCrossRef Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085PubMedCrossRef
28.
Zurück zum Zitat Sasaki R, Yasuda K, Abe E, Uchida N, Kawashima M, Uno T, Fujiwara M, Shioyama Y, Kagami Y, Shibamoto Y, Nakata K, Takada Y, Kawabe T, Uehara K, Nibu K, Yamada S (2011) Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys 82:626–634PubMedCrossRef Sasaki R, Yasuda K, Abe E, Uchida N, Kawashima M, Uno T, Fujiwara M, Shioyama Y, Kagami Y, Shibamoto Y, Nakata K, Takada Y, Kawabe T, Uehara K, Nibu K, Yamada S (2011) Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys 82:626–634PubMedCrossRef
Metadaten
Titel
Radiotherapy for solitary plasmacytoma of bone and soft tissue
Outcomes and prognostic factors
verfasst von
Yang-Gun Suh
Chang-Ok Suh
Jin Seok Kim
Soo-Jeong Kim
Hae Ok Pyun
Jaeho Cho
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 11/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1510-6

Weitere Artikel der Ausgabe 11/2012

Annals of Hematology 11/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.